NBE-Therapeutics, based in Basel, Switzerland, is a biotech company founded in 2012 to develop next-generation antibody drug conjugates (ADCs). The products in the NBE pipeline will be advanced to clinical proof of concept with the goal of improving treatment options for cancer patients. The company leverages proprietary platforms covering all aspects of ADC development: Transpo-mAbTM display technology for antibody discovery, SMAC-TechnologyTM for site-specific payload conjugation of toxins to antibodies, and a novel ultra-potent anthracycline-based toxin platform. SOTIO announced a collaboration with NBE on antibody-drug conjugates in October 2016 (see the press release here). The first joint program of SOTIO and NBE against an indislosed target is referred to as SO-N102. In November 2016, the company was financially backed by PPF Group, the Boehringer Ingelheim Venture Fund and additional private investors (see the press release here). For more information please visit: www.nbe-therapeutics.com.

This website uses cookies; by continuing to use this page, you consent to their use. About cookies